ESC: 6-Month DAPT Non-Inferior to Longer Tx Strategy

(MedPage Today) -- But problems with NIPPON trial highlight challenges of dual antiplatelet therapy research
via ESC: 6-Month DAPT Non-Inferior to Longer Tx Strategy
by